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Abstract: Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in 
green tea, has shown numerous health promoting effects acting through different pathways, 
as  antioxidant,  anti-inflammatory  and  anti-atherogenic  agent,  showing  gene  expression 
activity,  functioning  through  growth  factor-mediated  pathways,  the  mitogen-activated 
protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well 
as eliciting an amyloid protein remodeling activity. However, epidemiological inferences 
are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current 
knowledge on how to enhance bioavailability could be the answer to some of these issues. 
Furthermore,  dose  levels,  administration  frequency  and  potential  side  effects  remain  to  
be examined. 
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1. Introduction 
Since  our  letter  to  the  editor  of  blood  in  2007  “Epigallocatechin-3-gallate  (EGCG)  in  AL 
amyloidosis: a new therapeutic option?” [1], we have been confronted with followers and inveterate 
foes. Followers were the patients that followed the idea of drinking green tea as adjuvant to the current 
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offered therapy options. Inveterate foes were the college physicians, especially all those that worked 
on  scientific  projects  concerning  this  rare  disease  with  poor  prognosis  and  limited  therapeutic 
alternatives. Patients took the decision to go on and try this over-the-counter choice, sometimes even 
hidden from the negative posture of their attending physicians. This made it possible to extend our 
analysis from a case report to a report of cases in a cohort of these patients [2]. Furthermore, based on 
these findings, as well as on precedent basic research [3–5] and in spite of the difficulties concerning 
ethical matters related to the discussion as to whether EGCG is a drug or just a dietary supplement, a 
world leading research group is planning to start the first clinical trial with EGCG in patients with  
AL amyloidosis [6,7]. 
A quick look at EGCG and/or green tea on PubMed.gov [8] today results in a listing of more than 
4000 publications since 1940. The first publications on EGCG alone as main polyphenol in green tea is 
dated 1985; an actualized review on health promoting effects of EGCG from green tea is currently 
available [9] (Figure 1). From these publications, the impression arises that EGCG could prevent, or 
even cure almost every disease: a panacea-related discredit cannot be denied. However, basic research 
provides clear support for hypotheses on the use of EGCG, and  in spite of this  fact,  an apparent 
discrepancy  between those results and the occurrence of awaited effects  in clinical trials seems to 
linger on. 
Figure  1. Chemical structure of EGCG. Some  currently documented structure-function 
relationships  are  depicted  in  this  figure.  The  pyrogallol-type  structure  on  the  B-ring 
induces apoptosis and possesses strong antioxidative activity undergoing autooxidation to 
form reactive oxygen species [10,11]. The galloyl moiety (D-ring, gallate group) is the 
critical structure in the inhibition of fatty-acid synthase leading to cytotoxicity in human 
cancer  cells  [12].  Both  components  B  and  D  contribute  to  the  exertion  of  biological 
activities related to the cell-surface 67 kDa  laminin receptor [13,14]. EGCG  molecular 
docking fractions for amyloid remodeling activity are still not known. 
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Thus, the aim of this review is to discuss known issues that could lead to failure in the clinical use 
of  EGCG,  starting  with  the  concept  of  responders  and  non-responders,  going  through  its  erratic 
bioavailability and finally commenting on its possible side effects.  
2. Responders vs. Non-Responders 
Clinically relevant cytotoxic levels of EGCG in plasma [15] may not be reached in vivo through 
oral  ingestion  of  green  tea,  green  tea  extracts  or  pure  EGCG;  health  promoting  targets  of  this 
polyphenol will then take place through other pathways. The decrease of β-pleaded protein deposits in 
cardiac amyloidosis due to the protein remodeling activity of EGCG [3–5] may be closely monitored 
by assessment of left ventricular mass and function [1–4,6]. The degree of responsiveness to EGCG 
may  depend  on  its  plasma  and  tissue  bioavailability.  Thus,  since  the  latter  may  not  be  clinically 
possible  in  all  cases  at  the  moment,  at  least  close  controls  of  plasma  levels  of  EGCG  should  
be attempted.  
2.1. Monitoring Left Ventricular Wall Thickness and Function 
The reduction of left ventricular wall thickness in at least 2 mm [16], as well as left ventricular 
mass and improvement in global left ventricular function are expected changes in patients responders 
to  EGCG  [2]  in  cardiac  involvement  with  protein  deposits  due  to  immunoglobulin  light  chain 
amyloidosis (AL). Consequently, improvement functional class assessed with the New York Heart 
Association (NYHA) classification can be observed [2].  
However, not all patients with this targeted therapy will show the same effect. Our observations lead 
us to infer that there may be different types of responders to EGCG, as defined with the time to end-point 
(TEP, the interval until a 2 mm decrease in left ventricular wall thickness) could be documented. From 
the data in Table 2 [2] there were fast-responders: n = 4, with a TEP ≤ 3 months, slow-responders:  
n = 2, with a TEP ≤ 6 months, and very-slow-responders: n = 3, with a TEP ≤ 12 months. One patient 
showed the expected reduction in wall thickness with a 16 months delay. 
As in almost every known therapeutic approach in internal medicine, non-responders may also be 
found. We understand that the concept of non-responders to EGCG is a very dynamic one, since this 
unstable polyphenol shows a very variable bioavailability [17]. After correcting factors that lead to low 
levels  in  plasma,  a  non-responder  patient  may  turn  out  to  be  a  responder.  Therefore,  follow-up 
assessment of left ventricular wall thickness every 3 months may be necessary to monitor closely the 
degree of responsiveness of patients under EGCG medication in cardiac amyloidosis. 
2.2. Assessment of Plasma Levels of EGCG 
Quantification  of  plasma  EGCG  levels  is  necessary  in  order to  monitor  bioavailability  in  each 
patient at therapy start, but also during follow-up when changes in doses are made or new factors 
appear that may affect blood levels during the course of the disease. Non-responder patient could 
rapidly develop to a responder status after correcting factors that lead to low EGCG levels in plasma. 
Moreover,  measurement  of  EGCG  levels  in  plasma  is  fundamental  to  monitor  this  therapeutic 
approach, since the effects of EGCG take place in a plasma level dependent manner [6].  Int. J. Mol. Sci. 2011, 12                       
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Blood samples should be collected in EDTA containing tubes. As at pH above 7 EGCG oxidizes 
and dimerizes easily, blood samples must be immediately transferred to an ice bath and the plasma 
should  be  separated  from  the  cellular  fraction  by  centrifugation  at  4  °C.  Plasma  samples  in  an 
ascorbate EDTA solution should be stored at −80 °C until assessment using high-performance liquid 
chromatography with colorimetric array detector analysis [18]. 
3. Bioavailability of EGCG 
The  rather  poor  bioavailability  of  EGCG  needs  to  be  considered  when  we  extrapolate  results 
obtained in vitro to situations in vivo. There are known and still unknown reasons for erratic EGCG 
bioavailability. Pharmacokinetic parameters are useful for selecting the dose and dose frequency for 
intervention. Most of the ingested EGCG apparently does not get into the blood, since absorption takes 
place in the small gut and substantial quantities pass from the small to the large intestine where it 
undergoes further degradation by the action of local microbiota [17,19–21]. 
The peak plasma concentrations of EGCG are reached in 1–2 h in healthy subjects with one oral 
dose in the morning after an overnight fasting period. These levels diminish gradually to undetectable 
levels in 24 h. The elimination half-life of EGCG takes place at 3.4 ± 0.3 h [17]. 
3.1. Factors Influencing EGCG Bioavailability 
Considerable differences in the pharmacokinetic parameters in repeated experiments and among the 
individual  subjects  were  observed  in  published  information.  The  variations  among  the  repeated 
experiments were rather large in some subjects [17]. The following factors may play a role (Figure 2). 
Figure 2. Factors influencing EGCG bioavailability: Factors enhancing plasma levels of 
EGCG are listed to the left, those that diminish bioavailability can be found on the right. 
Most of these factors are easily modifiable. 
EGCG
● air contact oxidation
● gastrointestinal
inactivation
● Ca2+, Mg2+, metals
● COMT polymorphisms
● sulfation
● glucuronidation
cool & dry storage ●
fasting conditions ●
albumin ●
soft water ●
vitamin C ●
fish oil ●
piperine ●  
3.1.1. EGCG Oxidation Starts Already during Direct Contact with Air 
EGCG is stable under anaerobic conditions in vivo, although the mechanisms for its stabilization 
have not yet been fully characterized. Catechins with a pyrogallol-type structure on the B-ring, such as 
EGCG,  possess  strong  antioxidative  activity  and  undergo  autooxidation  to  form  reactive  oxygen 
species, resulting in polymerization and decomposition [11]. Int. J. Mol. Sci. 2011, 12                       
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3.1.2. EGCG May Undergo Gastrointestinal Inactivation  
Several other factors, including temperature [22], oxygen concentration, antioxidant concentration, 
metal ions, among others also affect stability of EGCG [13]. Hard water with high concentrations of 
Ca
2+ and Mg
2+, or even drinking milk together with EGCG leads to its inactivation [23]. Furthermore, 
new findings on bioavailability have shown that EGCG absorption takes places mostly in the small 
intestine, and that in subjects with a functioning colon it passes to the large intestine where it is broken 
down to phenolic acids by the action of colonic microflora [19–21]. 
3.1.3. EGCG Undergoes Liver Metabolism  
After oral absorption, tea catechins undergo extensive methylation, glucuronidation, and sulfation. 
Rapid methylation of EGCG is catalyzed by liver cytosolic catechol-O-methyltransferase. Methylation 
decreases  the  hydrophilicity  of  catecholic  compounds;  further  sulfation/glucuronidation  of  the 
methylated product is usually needed for the effective elimination of the methylation product from the 
body [24]. The level of methylation is influenced by polymorphisms of catechol-O-methyltransferase, 
but the scope of this effect has not yet been studied [17].  
3.1.4. EGCG Blood Transport and Stabilization Is Affected by the Level of Serum Albumin  
Human  serum  albumin  contributes  to  transport  and  stabilization  by  directly  preventing  EGCG 
oxidation through a reversible interaction with a higher affinity in alkaline conditions [11]. Hence, low 
serum albumin may decrease EGCG plasma levels. 
3.2. Optimizing EGCG Bioavailability 
We tested several options over the last years in an effort to enhance EGCG levels in plasma [6,18]. 
Scrupulous observation of the personal experiences and continuous queries in the published data were 
necessary to reach the current knowledge on optimizing EGCG bioavailability. We were able to reach 
the highest ever level of EGCG in plasma with the combination of EGCG (purity > 94%) without 
caffeine  taken  after  an overnight  fasting  period  together  with  200  mg  ascorbic  acid  and  1000 mg 
omega-3 fatty acids from salmon [6] (Figure 3). The following aspects should be taken in account for 
enhancing bioavailability of EGCG. 
3.2.1. Humidity and Temperature 
Since EGCG degradation is enhanced by relative humidity and temperature [22], capsules should be 
stored in cool and dry places, as well as hermetically closed recipients to avoid enhanced oxidation 
with air contact. Int. J. Mol. Sci. 2011, 12                       
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Figure  3.  Single  assessments  of  plasma  levels  of  EGCG  [6]  available  from  2008  on, 
measured 2 h after ingestion, depicted together with assessments of serum free light chains: 
Kappa,  Lambda  and  K/L  ratio,  as  well  as  international  normalized  ratio  (INR)  and 
interventricular  septum  thickness  (IVS).  EGCG assessments  were  undertaken  2  h  after 
ingestion,  referring  to  expected  peak  plasma  levels  [17,25].  (A)  Therapy  with  oral 
melphalan  plus  high-dose  dexamethasone  until  August  2006.  No  further  conventional 
chemotherapy  administered  later  on.  (B)  September  2006:  start  1.5–2  L/day  green  tea 
(GT). (C) June 2008: Start 150 mg EGCG t.i.d. instead of GT, because of oral fluid intake 
restriction due to progressive renal failure. (D) October 2008: dosage change to 450 mg 
EGCG t.i.d. + 200 mg vitamin C + 20 mg piperine each time. (E) December 2008: start 
continuous  ambulatory  peritoneal  dialysis  (CAPD);  EGCG  plasma  levels  decreased 
significantly,  at  the  same  time  high  EGCG  levels  were  found  in  CAPD  lavage  fluid.  
(F) July 2009: transurethral prostatectomy with further decrease EGCG levels. (G) Dosage 
correction to 900 mg EGCG t.i.d. + 200 mg vitamin C + 20 mg piperine. (H) November 
2009:  second  transurethral  prostatectomy  and  concurrent  peritonitis.  Further  dosage 
correction with 450 mg EGCG t.i.d. + 200 mg vitamin C + 10 mg piperine. (I) April 2011: 
final dosage optimizing with 600 mg EGCG t.i.d. + 200 mg vitamin C + 1000 mg omega-3 
fatty acids from salmon each time. No significant changes in FCL or INR were observed 
across the timeline.  A  significant  decrease  in  IVS thickness  under EGCG therapy  could  
be documented.  
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3.2.2. Intake with Empty Stomach 
One  oral  dose  in  the  morning  after  an  overnight  fasting  period  [17,18]  at  least  30  min  before 
breakfast, and a second dose in the afternoon with fasting period of at least 4 h, at least 30 min before 
dinner, seem to be necessary to reach high plasma levels of EGCG [6,18]. 
3.2.3. Hard Waters 
Since elevated concentration of calcium, magnesium and other metals in water would affect EGCG 
absorption [11], it is advisable to soften drinking hard waters with commercial available methods. 
3.2.4. Vitamin C  
Ascorbic acid alone may improve EGCG bioavailability [6,18] by preventing oxidation, the addition 
of sucrose may even accentuate this effect by enhancing its absorption in the digestive tract [26]. 
3.2.5. Fish Oil 
Omega-3 polyunsaturated fatty acids may enhance not only oral bioavailability of EGCG but may 
also improve its efficacy as shown in previous studies [27–29]. 
3.2.6. Piperine 
This black pepper alkaloid could serve as a potential dietary modulator of the bioavailability of 
EGCG by inhibiting its glucuronidation in the small intestines, as well as inhibit gastric emptying and 
gastrointestinal transit, which may result in increased absorption [6,18,30]. 
Further  efforts  in  improving  EGCG  bioavailability  with  promising  approaches  are  being 
undertaken,  such  as  the  encapsulation  of  EGCG  in  chitosan  nanoparticles,  enhancing  intestinal 
absorption through polyphenol stabilization [31], or the design and semisynthesis O-acyl derivatives of 
EGCG  [32],  or  the  solid-phase  synthesis  of  EGCG  derivatives  [33],  or  even  considering  another 
application way, for instance the transdermal delivery of EGCG [34]. 
4. Side Effects of EGCG 
Providing EGCG is a pharmakon (ancient Greek word meaning at the same time remedy and poison), 
side effects should also be expected. There is an important lack of clinical studies referring to dose 
levels for different diseases, daily administration frequency and side effects in long term therapy. A 
daily  dose  of  800  mg  caffeine  free  EGCG  for 4  weeks  was  shown  to  be  safe  and  well  tolerated  
in healthy human subjects [25]. However, inherent to different effects of EGCG in several levels, and 
due  to  possible  contamination  with  herbicides  and/or  pesticides,  some  degree  of  side  effects  can  
be expected:  Int. J. Mol. Sci. 2011, 12                       
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4.1. Anxiolytic Activity 
EGCG produces some behavioral effects corresponding to a benzodiazepine-like profile, inducing 
anxiolytic  activity  which  could  result  from  an  interaction  with  γ-aminobutyric  acid  (GABAA)  
receptors  [35–37].  In  addition  to  an  interaction  with  benzodiazepin  receptors,  EGCG  may  inhibit 
spontaneous  excitatory  synaptic  transmission  independently  of  GABA  receptor  activation.  This 
inhibition could be due to a direct antagonism  of glutamate receptors. Alternatively,  EGCG could 
decrease  spontaneous  synaptic  transmission  by  attenuating  neuronal  firing  by  hyperpolarization  as 
shown in medial vestibular neurons [37]. 
4.2. Hypoglycemic Activity 
EGCG suppresses hepatic gluconeogenesis at concentrations that are not toxic to hepatocytes and are 
reachable by ingestion of green tea or pure EGCG through 5′-AMP-activated protein kinase mediated by 
the  Ca
2+/calmodulin-dependent  protein  kinase,  both  dependent  on  production  of  reactive  oxygen 
species [38]. Furthermore, on one hand EGCG mimics insulin action on the transcription factor Forkhead 
box protein O1 (FOXO1a) and elicits in this way cellular responses in the presence and absence of 
insulin [39] and on the other hand, EGCG inhibits β-2-aminobicyclo-(2.2.1)-heptane-2-carboxylic acid 
(BCH)  stimulated  insulin  secretion  by  pancreatic  β-cells  mediated  by glutamate dehydrogenase [40]. 
These effects acting together with anxiolytic activity could explain some cases of dizziness referred to 
by patients taking high oral EGCG doses. 
4.3. Hypochromic Anemia 
Phenolic compounds such as EGCG are potent inhibitors of iron absorption in a dose-dependent 
fashion depending on the content of total polyphenols, interfering with its assimilation by the complex 
formation of the gastro-intestinal lumen [41–43]. 
4.4. Liver and Kidney Failure 
EGCG  and  other  phenolic  compounds  may  be  hepatotoxic  at  higher  doses  [44,45].  Moreover, 
hepatotoxicity  related  to  the  consumption  of  high  doses  of  tea-based  dietary  supplements  
(10–29 mg/kg/day) has been reported [46], but the involvement of potentially hepatotoxic agents such 
as endosulfan, an inexpensive organochlorine pesticide that builds up in the environment extensively 
used in some green tea plantations [47], was not conclusively ruled out. Chronic exposure to low doses 
of endosulfan in an additive manner may be hepatotoxic, as well as nephrotoxic [48], but clinical 
studies in humans are lacking, due to evident ethical considerations. 
5. Conclusions 
The  introduction  of  great  therapeutic  agents  into  modern  clinical  practice  [49],  as  well  as  the 
scientific development of new therapy options in medical history started frequently on the basis of 
naturally available products. Even though green tea health benefits have been known for thousands of 
years, basic research  findings on  its main active component, EGCG, have proven to be extremely Int. J. Mol. Sci. 2011, 12                       
 
5600
promising in numerous fields in the last decades. Furthermore, current knowledge force us to go on 
from  just  drinking  daily  large  amounts  of  green  tea,  or  taking  over-the-counter  green  tea  extract 
products, to prescribing medically manufactured pure EGCG, especially for parenteral application, or 
in combination with enhancers of its bioavailability. 
The numerous health benefits of EGCG as a prophylactic, but also as a therapeutic, agent acting 
through  different  pathways  are  well  documented  in  the  literature.  Conflicting  epidemiological 
inferences  and  discrepancies  between  in  vitro  and  in  vivo  studies  may  be  due  to  its  erratic 
bioavailability.  Aspects  concerning  these  facts,  but  also  relating  to  dose  levels,  administration 
frequency and potential side effects remain to be addressed in future clinical trials. 
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